Canadian Generic Pharmaceutical Importing/Manufacturing Capacity Study - February 2022

Investing in the sector can allow companies to increase the volume and breadth of products that are manufactured and increase the degree of vertical integration of manufactures. [...] If Canada were to place more emphasis on its manufacturing capabilities, several key factors would need to be strengthened, including greater support through federal and provincial government incentives, understanding the risks in the economy and the labour market, the associated minimum operating costs and technology requirements for parts and equipment, and the ability to import the right raw ma. [...] This includes, strengthening federal and provincial government incentives, understanding the risks in the economy and the labour market, the associated minimum operating costs and technology requirements for parts and equipment as well as the ability to import the right raw materials and APIs in order to reliably manufacture products in Canada. [...] 30 | Manufacturing Capacity Study 4.2 Government incentives and regulation With increased attention on Canada’s life sciences sector and the importance of securing a domestic supply of generic pharmaceuticals, the federal and provincial governments have the opportunity to provide supports and make investments that will shape the future of the sector. [...] The COVID-19 pandemic increased both the government and the public’s attention to Canada’s pharmaceutical supply chain and highlighted need to invest in domestic infrastructure and manufacturing capabilities in the pharmaceutical sector.